Search

Amgen Inc

Закрыт

СекторЗдравоохранение

358.19 0.34

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

353

Макс.

360.6

Ключевые показатели

By Trading Economics

Доход

486M

1.8B

Продажи

-1.3B

8.6B

P/E

Средняя по отрасли

25.5

60.549

Прибыль на акцию

5.15

Дивидендная доходность

2.58

Рентабельность продаж

21.107

Сотрудники

31,500

EBITDA

-1.2B

3.9B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

-0.36% downside

Дивиденды

By Acuity

Дивидендная доходность

Средняя по отрасли

2.58%

2.22%

Следующий отчет о доходах

4 авг. 2026 г.

Дата следующей выплаты дивидендов

11 сент. 2026 г.

Следующая эксдивидендная дата

21 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

14B

198B

Предыдущая цена открытия

357.85

Предыдущая цена закрытия

358.19

Новостные настроения

By Acuity

5%

95%

2 / 342 Рейтинг в Healthcare

Amgen Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

13 июл. 2026 г., 19:46 UTC

News

Shares lower today despite price target increases from Guggenheim, UBS.

10 июл. 2026 г., 23:16 UTC

Amgen Inc. shares are higher in after-market trading, remaining near the upper end of their one-month range amid rising U.S. Treasury yields.

9 июл. 2026 г., 23:01 UTC

Amgen Inc shares are trading lower in after-market hours, following unusual trading activity with no specific news identified to explain the decline.

8 июл. 2026 г., 23:21 UTC

Amgen Inc shares are lower in after-market hours, reflecting broader market declines amid geopolitical tensions and a significant drop in the DAX 30 Index.

7 июл. 2026 г., 19:06 UTC

News

Truist Securities raised Amgen's price target to $340, maintaining a Hold rating. Shares are advancing, reflecting positive sentiment and long-term value creation.

6 июл. 2026 г., 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

2 июл. 2026 г., 23:06 UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

1 июл. 2026 г., 19:11 UTC

Social Media

Amgen Inc shares are lower amid social media discussions on AI's impact on drug discovery and client platform risk perceptions in the biopharma sector.

29 июн. 2026 г., 19:11 UTC

News

Amgen Inc shares are higher today, supported by a broader market rally and investor confidence from South Korea's $576 billion investment plan in technology.

26 июн. 2026 г., 23:06 UTC

News

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

25 июн. 2026 г., 23:01 UTC

Amgen Inc shares are higher in after-market trading, continuing a recent positive trend with four consecutive sessions of gains. No specific news was identified.

24 июн. 2026 г., 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23 июн. 2026 г., 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22 июн. 2026 г., 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18 июн. 2026 г., 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17 июн. 2026 г., 19:53 UTC

Macro Event

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16 июн. 2026 г., 19:22 UTC

News

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15 июн. 2026 г., 21:09 UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12 июн. 2026 г., 19:51 UTC

News

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11 июн. 2026 г., 23:06 UTC

News

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10 июн. 2026 г., 23:51 UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9 июн. 2026 г., 19:56 UTC

News

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8 июн. 2026 г., 20:06 UTC

News

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5 июн. 2026 г., 23:01 UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.

4 июн. 2026 г., 23:51 UTC

News

Amgen will present at the Goldman Sachs Global Healthcare Conference on June 9, 2026. Shares are trading higher in after-market hours.

3 июн. 2026 г., 23:41 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and strong performance above its 20-day moving average.

2 июн. 2026 г., 23:02 UTC

Amgen Inc. shares are lower in after-market trading, continuing a trend of declines over the last three sessions and remaining below the 20-day moving average.

1 июн. 2026 г., 20:02 UTC

Amgen Inc. shares are lower today, dropping below Friday's close and nearing the lower end of their one-month trading range. No specific news was identified.

29 мая 2026 г., 20:06 UTC

Amgen Inc's shares are higher today, reflecting a slight gain since Thursday's close. The stock remains stable within its one-month trading range.

28 мая 2026 г., 23:56 UTC

Amgen Inc's shares are higher in after-market hours, maintaining stability above the 20-day moving average and within the one-month trading range.

Сравнение c конкурентами

Изменение цены

Amgen Inc Прогноз

Целевая цена

By TipRanks

-0.36% падение

Прогноз на 12 месяцев

Средняя 359.17 USD  -0.36%

Максимум 427 USD

Минимум 300 USD

Основано на мнении 24 аналитиков Wall Street, спрогнозировавших целевые цены для Amgen Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

24 ratings

10

Покупка

13

Удержание

1

Продажа

Настроения

By Acuity

2 / 342Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat